vs
AVANOS MEDICAL, INC.（AVNS）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
AVANOS MEDICAL, INC.的季度营收约是REPUBLIC BANCORP INC的1.9倍（$180.9M vs $94.3M），REPUBLIC BANCORP INC净利率更高（24.2% vs -0.7%，领先24.9%），REPUBLIC BANCORP INC同比增速更快（5.3% vs 0.7%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $21.3M），过去两年AVANOS MEDICAL, INC.的营收复合增速更高（4.4% vs -11.5%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
AVNS vs RBCAA — 直观对比
营收规模更大
AVNS
是对方的1.9倍
$94.3M
营收增速更快
RBCAA
高出4.6%
0.7%
净利率更高
RBCAA
高出24.9%
-0.7%
自由现金流更多
RBCAA
多$139.8M
$21.3M
两年增速更快
AVNS
近两年复合增速
-11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $94.3M |
| 净利润 | $-1.3M | $22.8M |
| 毛利率 | 47.5% | — |
| 营业利润率 | 1.4% | 29.3% |
| 净利率 | -0.7% | 24.2% |
| 营收同比 | 0.7% | 5.3% |
| 净利润同比 | 99.7% | 20.0% |
| 每股收益（稀释后） | $-0.02 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRBCAA
| Q4 25 | $180.9M | $94.3M | ||
| Q3 25 | $177.8M | $93.5M | ||
| Q2 25 | $175.0M | $93.8M | ||
| Q1 25 | $167.5M | $135.8M | ||
| Q4 24 | $179.6M | $89.5M | ||
| Q3 24 | $170.4M | $88.1M | ||
| Q2 24 | $171.7M | $86.9M | ||
| Q1 24 | $166.1M | $120.3M |
净利润AVNSRBCAA
| Q4 25 | $-1.3M | $22.8M | ||
| Q3 25 | $-1.4M | $29.7M | ||
| Q2 25 | $-76.8M | $31.5M | ||
| Q1 25 | $6.6M | $47.3M | ||
| Q4 24 | $-397.3M | $19.0M | ||
| Q3 24 | $4.3M | $26.5M | ||
| Q2 24 | $1.8M | $25.2M | ||
| Q1 24 | $-900.0K | $30.6M |
毛利率AVNSRBCAA
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
营业利润率AVNSRBCAA
| Q4 25 | 1.4% | 29.3% | ||
| Q3 25 | 0.1% | 40.4% | ||
| Q2 25 | -42.6% | 43.0% | ||
| Q1 25 | 6.1% | 44.1% | ||
| Q4 24 | -233.0% | 25.8% | ||
| Q3 24 | 7.0% | 38.4% | ||
| Q2 24 | 3.7% | 37.0% | ||
| Q1 24 | 2.4% | 32.2% |
净利率AVNSRBCAA
| Q4 25 | -0.7% | 24.2% | ||
| Q3 25 | -0.8% | 31.8% | ||
| Q2 25 | -43.9% | 33.5% | ||
| Q1 25 | 3.9% | 34.8% | ||
| Q4 24 | -221.2% | 21.2% | ||
| Q3 24 | 2.5% | 30.1% | ||
| Q2 24 | 1.0% | 29.0% | ||
| Q1 24 | -0.5% | 25.4% |
每股收益（稀释后）AVNSRBCAA
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-1.66 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.04 | — | ||
| Q1 24 | $-0.02 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $220.0M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $1.1B |
| 总资产 | $1.1B | $7.0B |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRBCAA
| Q4 25 | $89.8M | $220.0M | ||
| Q3 25 | $70.5M | $484.2M | ||
| Q2 25 | $90.3M | $484.8M | ||
| Q1 25 | $97.0M | $793.0M | ||
| Q4 24 | $107.7M | $432.2M | ||
| Q3 24 | $89.0M | $530.9M | ||
| Q2 24 | $92.2M | $400.1M | ||
| Q1 24 | $75.8M | $546.4M |
总债务AVNSRBCAA
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRBCAA
| Q4 25 | $778.2M | $1.1B | ||
| Q3 25 | $778.0M | $1.1B | ||
| Q2 25 | $776.3M | $1.1B | ||
| Q1 25 | $839.4M | $1.0B | ||
| Q4 24 | $828.5M | $992.0M | ||
| Q3 24 | $1.2B | $979.7M | ||
| Q2 24 | $1.2B | $955.4M | ||
| Q1 24 | $1.2B | $935.6M |
总资产AVNSRBCAA
| Q4 25 | $1.1B | $7.0B | ||
| Q3 25 | $1.1B | $7.0B | ||
| Q2 25 | $1.0B | $7.0B | ||
| Q1 25 | $1.1B | $7.1B | ||
| Q4 24 | $1.2B | $6.8B | ||
| Q3 24 | $1.7B | $6.7B | ||
| Q2 24 | $1.7B | $6.6B | ||
| Q1 24 | $1.7B | $6.9B |
负债/权益比AVNSRBCAA
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $161.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 170.9% |
| 资本支出强度资本支出/营收 | 3.8% | 7.5% |
| 现金转化率经营现金流/净利润 | — | 7.37× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $288.6M |
8季度趋势，按日历期对齐
经营现金流AVNSRBCAA
| Q4 25 | $28.2M | $168.2M | ||
| Q3 25 | $14.0M | $33.3M | ||
| Q2 25 | $6.8M | $8.4M | ||
| Q1 25 | $25.7M | $93.2M | ||
| Q4 24 | $57.9M | $149.0M | ||
| Q3 24 | $23.0M | $51.3M | ||
| Q2 24 | $27.8M | $4.0M | ||
| Q1 24 | $-8.0M | $71.2M |
自由现金流AVNSRBCAA
| Q4 25 | $21.3M | $161.1M | ||
| Q3 25 | $7.0M | $30.8M | ||
| Q2 25 | $-4.2M | $5.2M | ||
| Q1 25 | $19.0M | $91.6M | ||
| Q4 24 | $53.1M | $143.2M | ||
| Q3 24 | $20.0M | $49.8M | ||
| Q2 24 | $21.9M | $2.7M | ||
| Q1 24 | $-12.1M | $69.1M |
自由现金流率AVNSRBCAA
| Q4 25 | 11.8% | 170.9% | ||
| Q3 25 | 3.9% | 32.9% | ||
| Q2 25 | -2.4% | 5.5% | ||
| Q1 25 | 11.3% | 67.4% | ||
| Q4 24 | 29.6% | 160.0% | ||
| Q3 24 | 11.7% | 56.5% | ||
| Q2 24 | 12.8% | 3.1% | ||
| Q1 24 | -7.3% | 57.5% |
资本支出强度AVNSRBCAA
| Q4 25 | 3.8% | 7.5% | ||
| Q3 25 | 3.9% | 2.6% | ||
| Q2 25 | 6.3% | 3.5% | ||
| Q1 25 | 4.0% | 1.2% | ||
| Q4 24 | 2.7% | 6.5% | ||
| Q3 24 | 1.8% | 1.7% | ||
| Q2 24 | 3.4% | 1.5% | ||
| Q1 24 | 2.5% | 1.7% |
现金转化率AVNSRBCAA
| Q4 25 | — | 7.37× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | 3.89× | 1.97× | ||
| Q4 24 | — | 7.84× | ||
| Q3 24 | 5.35× | 1.93× | ||
| Q2 24 | 15.44× | 0.16× | ||
| Q1 24 | — | 2.33× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RBCAA
暂无分部数据
